A Study of MK-7240 in Healthy Participants (MK-7240-009)
- Sponsor
- Merck Sharp & Dohme LLC
- Study ID
- NCT07405177
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Tulisokibart Form 1 — BIOLOGICALSolution for injection.
- Tulisokibart Form 2 — BIOLOGICALSolution for injection.
Study Details
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Key Dates
- Start date
- Mar 5, 2026
- Status verified
- Jun 2026
- Primary completion
- Sep 3, 2026
- Completion
- Sep 3, 2026
Study Design
- Enrollment
- 330 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Arm 1: Tulisokibart Form 1Participants will receive tulisokibart form 1.
- Experimental: Arm 2: Tulisokibart Form 2Participants will receive tulisokibart form 2.
Primary Outcome Measure
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart [ Time Frame: At designated timepoints up to 14 weeks ]
Related Studies
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Mapping Auricular Vagus Nerve CircuitryEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group TestingRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Evaluation and Optimization of Ultrasound and/or MRI Hardware and SoftwareRecruiting · State University of New York - Upstate Medical University · Syracuse, New York